SuperworthKestra Medical Technologies revenue KMTS
Sales by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jul 31, 2026
- $106.7M
- Latest quarter, Q1 FY27
- $31M
- +60% on a year earlier
- Fiscal year 2026
- $95.1M
- +59% on the year before
Kestra Medical Technologies' revenue was $106.7M over the twelve months to Jul 31, 2026, up 61% on a year earlier.
In its latest quarter, Q1 FY27, it was $31M, up 60% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2026 | $95.1M | +59% |
| FY2025 | $59.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | $31M | +60% | $106.7M | |
| Q4 FY26 | $28.6M | +66% | $95.1M | |
| Q3 FY26 | $24.6M | +63% | $83.7M | |
| Q2 FY26 | $22.6M | +53% | $74.3M | |
| Q1 FY26 | $19.4M | +52% | $66.4M | |
| Q4 FY25 | $17.2M | n/a | $59.8M | |
| Q3 FY25 | $15.1M | n/a | n/a | |
| Q2 FY25 | $14.7M | n/a | n/a | |
| Q1 FY25 | $12.8M | n/a | n/a |
Against its peers
Companies in Medical - Instruments & Supplies nearest Kestra Medical Technologies' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| KMTSKestra Medical Technologies | $106.7M | +61% a year |
| LMATLemaitre Vascular | $262.4M | +12% a year |
| EYENational Vision | $2B | +8% a year |
| INSPInspire Medical Systems | $898.7M | +4% a year |
| CDRECadre | $685.6M | +20% a year |
| UFPTUFP Technologies | $631.6M | +7% a year |
| BVSBioventus | $581.8M | +3% a year |
| STAAStaar Surgical | $339.6M | +51% a year |
| IRMDIradimed | $86.3M | +11% a year |
| ATRCAtriCure | $569.6M | +14% a year |
| WRBYWarby Parker | $911.6M | +11% a year |
| Peer median | $606.7M |
Where Kestra Medical Technologies ranks
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Kestra Medical Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.